Most Accessed Forms

VENTAVIS Enrollment Forms

Have questions?
Help is available.

Call us for help

1-866-ACTELION
(1-866-228-3546)

Mon-Fri, 8 am-8 pm ET

Email an Actelion Pathways
Case Manager for assistance

Email a Case Manager

Support and Financial Assistance for VENTAVIS® (iloprost) Inhalation Solution

An Actelion Pathways® Case Manager works with your office, the specialty pharmacy, and your patients. When patients are prescribed an Actelion PAH medication, they will be contacted by the specialty pharmacy.

Actelion Pathways can help by:

  • Answering questions about filling prescriptions with a specialty pharmacy
  • Coordinating with you and the specialty pharmacy to help your patients access medicine
  • Informing patients of any financial assistance programs for which they may be eligible

Therapy Access Managers (TAMs)

TAMs serve as the primary field-based lead to support patient access, including starting and staying on Actelion therapies.

See a map of territories to contact the TAM in your area.

Connecting with financial assistance

There is a program that can provide financial assistance to your patients taking VENTAVIS. Contact an Actelion Pathways Case Manager to learn more about:

  • Patient Assistance Program (PAP)—A yearly program that helps patients who are uninsured or underinsured to receive medicine at no cost*
  • Independent foundations—There may be support available from independent third-party patient support foundations. An Actelion Pathways Case Manager can provide general information about resources

*Uninsured: Patient who does not have insurance coverage. Underinsured: Patients who are uninsured or the cost of their medicine is covered by insurance, but are unable to afford the out-of-pocket costs.

Support resources

There are also independent organizations that may be able to offer support to your patients.

  • Pulmonary Hypertension Association is dedicated to increasing awareness and advocacy by providing information about PAH to both physicians and patients. Visit their website to learn more
  • The Scleroderma Foundation is a site for scleroderma patients, caregivers, and family members—dedicated to support, education, and research. Visit their website to learn more

Contact an Actelion Pathways Case Manager today. He or she can assist your patients with the support and services provided by Actelion. Call 1-866-ACTELION (1-866-228-3546) Mon-Fri, 8 am-8 pm ET.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Syncope

  • Vital signs should be monitored while initiating VENTAVIS. Hypotension leading to syncope has been observed; VENTAVIS should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.
See More

INDICATION

VENTAVIS® (iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Syncope

  • Vital signs should be monitored while initiating VENTAVIS. Hypotension leading to syncope has been observed; VENTAVIS should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.

Pulmonary Venous Hypertension

  • Stop VENTAVIS immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
See More

Indication

VENTAVIS® (iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Bronchospasm

  • VENTAVIS inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.

ADVERSE REACTIONS

Serious Adverse Events

  • Serious adverse events reported include congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure.

Adverse Events

  • Adverse events reported in a Phase 3 clinical trial occurring with a ≥3% difference between VENTAVIS patients and placebo patients were vasodilation (flushing) (27% vs 9%), increased cough (39% vs 26%), headache (30% vs 20%), trismus (12% vs 3%), insomnia (8% vs 2%), nausea (13% vs 8%), hypotension (11% vs 6%), vomiting (7% vs 2%), alkaline phosphatase increased (6% vs 1%), flu syndrome (14% vs 10%), back pain (7% vs 3%), tongue pain (4% vs 0%), palpitations (7% vs 4%), syncope (8% vs 5%), GGT increased (6% vs 3%), muscle cramps (6% vs 3%), hemoptysis (5% vs 2%), and pneumonia (4% vs 1%).

DRUG INTERACTIONS

Antihypertensives and Vasodilators

  • VENTAVIS has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.

Anticoagulants and Platelet Inhibitors

  • VENTAVIS also has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants or platelet inhibitors.

Please see full Prescribing Information.